Eddingpharm (zhuhai) Co., Ltd.
Clinical trials sponsored by Eddingpharm (zhuhai) Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug shows promise for rare high cholesterol condition Results expected Oct 2026 (estimated)
-
Can a new RNA drug tame high blood fats?
Disease control Not yet recruitingThis trial tests whether EDP167, an experimental RNA drug, can safely lower triglycerides and other harmful fats in the blood of adults with mixed dyslipidemia. Participants receive one of three doses of EDP167 or a placebo as an injection every 12 weeks, alongside their usual st…
Phase 2 • Sponsor: Eddingpharm (Zhuhai) Co., Ltd. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Triple-Action antibody takes aim at advanced breast cancer
Disease control Not yet recruitingThis trial is testing an experimental drug called GB268, a tri-specific antibody that targets three key pathways involved in cancer growth. It is being studied alone or in combination with other treatments in people with locally advanced or metastatic breast cancer. The goal is t…
Phase 1/2 • Sponsor: Eddingpharm (Zhuhai) Co., Ltd. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC